To accelerate breakthroughs, the Damon Runyon Foundation provides today's best young scientists with funds to pursue innovative cancer research.
July 2, 2007
Nobel Laureate, Susumu Tonegawa, PhD (Damon Runyon Fellow '69-'70) and colleagues reported on a breakthrough with therapeutic implications for Fragile X syndrome, the most common genetic form of mental retardation and autism. Tonegawa and his co-workers found that inhibition of p21-activated kinase reverses the symptoms of fragile X syndrome in mouse models of the disease.